Head and neck cancer patients with HPV-positive tumors tend to survive longer and are more responsive to treatment compared with patients with HPV-negative tumors, according to a study published online February 12 in the Journal of the National Cancer Institute.
Human papillomavirus has been shown to be involved in the development of some head and neck cancers, particularly cancers of the upper throat, or oropharynx. Retrospective studies suggest that patients with HPV-positive tumors generally have a better prognosis than those patients with HPV-negative tumors, but these findings must be confirmed in clinical trials.
To examine the association between HPV infection and cancer prognosis, Maura Gillison, M.D., Ph.D., of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore and colleagues followed 96 patients with stage III or IV cancer of the oropharynx or larynx (voicebox). All of the patients were enrolled in the same phase II clinical trial and received the same treatment. The researchers collected data on the patients' response to treatment and their survival times, as well as whether their tumors were HPV-positive or -negative.
Patients with HPV-positive tumors had higher response rates after chemoradiation therapy, compared to patients with HPV-negative tumors (84 percent vs. 57 percent), and their two-year overall survival rates were also higher (95 percent vs. 62 percent).
"Our data suggest that the risks and benefits of...therapies should be considered separately for HPV-positive and -negative patients," the authors write.
Contact: Vanessa Wasta, media relations, Sidney Kimmel Comprehensive Cancer Center, (410) 955-1287, firstname.lastname@example.org
Citation: Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison ML. Improved Survival of Patients With Human Papillomavirus - Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial. J Natl Cancer Inst 2008;100: 261 - 269
Note to Reporters:
We have started up an e-mail list to alert reporters when papers are available on the EurekAlert site. If you would be interested on being on this list, please let us know at email@example.com. The content will continue to be available through EurekAlert's e-mail system and our EurekAlert page.
The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.